NELSON
2020
Dutch-Belgian Lung Cancer Screening Trial
In 15,789 high-risk men (and a small subgroup of women), volume-based LDCT at baseline, 1, 3 and 5.5 years reduced lung-cancer mortality at 10 years compared with no screening.
Result
Efficacy: Lung-cancer mortality at 10 yearsRR 0.76 (95% CI 0.61-0.94)
Below 1 favours volume-based LDCT at baseline, 1, 3 and 5.5 years, above 1 favours no screening.
Also reported: Women RR 0.67 (95% CI 0.38–1.14).
- Subtopic
- Low-dose CT
- Design
- Multicentre RCT, Netherlands/Belgium
- Relevance
- Important: one of several pillars.
- Source
- de Koning HJ, et al. N Engl J Med. 2020;382(6):503-513.doi 10.1056/NEJMoa1911793
Discussion & critique
Confirmed NLST in a European population versus no-screening; volume-based criteria reduced false positives.